logo

Auris Medical Holding Ag (EARS)



Trade EARS now with
  Date
  Headline
7/3/2019 9:03:24 AM Auris Medical Completes Enrollment In Phase 1b Proof-of-concept Trial Of AM-201
2/1/2019 7:33:21 AM Auris Medical Announces Full Repayment Of Hercules Loan Facility
1/29/2019 7:35:19 AM Auris Medical Intends To Relocate Domicile From Zug, Switzerland To Hamilton, Bermuda
12/6/2018 7:33:19 AM Auris Medical Announces Strategic Expansion For Intranasal Betahistine Development Program
11/20/2018 9:23:12 AM Auris Medical Says FDA Supports Planned Conduct Of Multiple Dose Phase 1 Trial With AM-201
11/15/2018 6:48:15 AM Auris Medical Holding Q3 Net Loss CHF 3.0 Mln Or CHF 0.14 Per Share
10/17/2018 6:48:44 AM Auris Medical Reports Positive Results From Second Phase 1 Clinical Trial With Intranasal Betahistine
8/30/2018 8:16:37 AM Auris Medical Gets FDA Guidance At Type C Meeting For AM-111 In Treatment Of Sudden Sensorineural Hearing Loss
8/15/2018 6:48:48 AM Auris Medical Q2 Net Loss CHF 3.1 Mln Or CHF 0.50/Shr Vs Loss CHF 5.4 Mln Or CHF 1.22/Shr Last Year
5/30/2018 7:46:47 AM Auris To Host Key Opinion Leader Call Focused On AM-201 Program For Treating Major Side Effects Of Antipsychotics
5/15/2018 6:47:58 AM Auris Medical Q1 Net Loss CHF 1.7 Mln Or CHF 0.30/Shr Vs Loss CHF 8.4 Mln Or CHF 2.15/Shr Last Year
5/4/2018 6:48:47 AM Auris Medical Announces Publication Related To AM-111 In Peer-Reviewed Scientific Journal
4/9/2018 6:49:38 AM Auris Medical Announces Voluntary Early Repayment Of Part Of Its Loan Facility With Hercules Capital
3/29/2018 7:03:40 AM Auris Regains Compliance With Nasdaq's Minimum Bid Price Requirement